

REMARKS**Claim Amendments**

Claims 1-2, 4-9, 11-40 and 45-52 were pending. Claims 1-2, 17, 19, 22, 29 and 48 have been amended to correct typographical errors. *No new matter has been added.* Applicants reserve the right to pursue the claims as originally filed in this or subsequent applications.

Restriction Requirement

The Examiner has required restriction among the following inventions in the above-identified application:

Invention I: Claims 1, 2, 4-9, 11-37, 45 and 48, drawn to an isolated **peptide** comprising Lo1 p1 T cell epitope, a pharmaceutical composition comprising said peptide and a kit comprising said peptide;

Invention II: Claims 38, 50, and 52, drawn to an isolated **nucleic acid molecule** comprising a nucleotide sequence encoding an isolated polypeptide comprising a Lo1 p1 T cell epitope, a pharmaceutical composition comprising said nucleic acid molecule and a kit comprising said nucleic acid molecule;

Invention III: Claims 39 and 40, drawn to a **method for treatment and/or prophylaxis** of a condition in a subject comprising administering to said subject an effect[ive] amount of an isolated **peptide** comprising a Lo1 p1 T cell epitope;

Invention IV: Claims 46 and 47, drawn to a **method of diagnosing** or monitoring a condition in a mammal comprising screening for Lo1 p1 and/or Lo1 p5 reactive T cells and/or antibodies utilizing an isolated **peptide** comprising a Lo1 p1 T cell epitope;

Invention V: Claim 49, drawn to a **method for treatment and/or prophylaxis** of a condition in a subject comprising administering to said subject an effect[ive] amount of a **nucleic acid** encoding an isolated peptide comprising a Lo1 p T cell epitope; and

Invention VI: Claim 51, drawn to a **method of diagnosing or monitoring** a condition in a mammal comprising screening for Lol p1 and/or Lol p5 reactive T cells and/or antibodies **utilizing an isolated nucleic acid molecule** comprising a Lol p T cell epitope.

Election

Applicants hereby elect Group I (claims 1, 2, 4-9, 11-37, 45 and 48), without traverse, for continued examination (drawn to an isolated peptide comprising Lol p1 T cell epitope, a pharmaceutical composition comprising said peptide and a kit comprising said peptide).

Additionally, Applicants understand that the nonelected process claims which depend from the elected product claims and include all of the limitations of the elected product claims will be rejoined in accordance with MPEP § 821.04, once the product claims are found allowable.


CONCLUSION

If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' attorney at (617) 227-7400.

Applicants believe no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 12-0080, under Order No. JKJ-003US from which the undersigned is authorized to draw.

Dated: May 19, 2008

Respectfully submitted,

By 

Jill Gornly Sloper, Esq.

Registration No.: 60,760

LAHIVE & COCKFIELD, LLP

One Post Office Square

Boston, Massachusetts 02109-2127

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicants